Contrast-induced nephropathy (CIN) is an iatrogenic medical event for which there is still no successful clinical therapy and is the third cause of kidney failure acquired in a hospital1. Increasing evidences in experimental models suggests that this disease is associated with tubular and renal vascular injury triggered directly by oxidative stress2. Thus, investigating substances known to be antioxidants may be a relevant strategy for the prevention of CIN3. The aim was evaluate whether the phytotherapic Silybum marianum - "silymarin" (SIL) can attenuate renal damage in mice submitted to CIN. For the study male adults Swiss mice subdivided into six experimental groups CEUA(403-2016) : three groups pre-treated orally with SIL (50, 200 and 300 mg / kg), a pre-treated group with N-acetylcysteine (200 mg / kg), a non-pretreatment group receiving vehicle and a control group, which also received vehicle, for 5 days prior to induction of CIN. After 24 hours of induction of nephropathy with the combination of a prostaglandin inhibitor synthesis (indomethacin), an inhibitor of nitric oxide synthesis (L-NAME) and the meglumine amidotrizoate contrast, the animals were euthanized with sodium pentobarbital (60 mg / Kg, ip) for blood collection (biochemical dosages: Urea, Creatinine and Cystatin C serum). Preliminary results indicate biochemical that in a dose-dependent manner SIL treatment in the CIN model reduced urea by (60%, p <0.05), with a tendency to decrease creatinine (30%, p> 0.05) and cystatin C (50% w> 0.05) as well. These preliminary nephroprotection data suggest that silymarin may be used as a novel therapeutic strategy to prevent contrast-induced nephropathy, probably because of its antioxidant properties, which will be confirmed in subsequent experiments.